AGM Statement

RNS Number:0936X
Entelos Inc.
23 May 2007


For immediate release:

                                  Entelos Inc.
                                  Result of AGM


Entelos, Inc. (LSE:ENTL), a leading life sciences company building predictive
computer models of human physiology and 'virtual patients' for drug discovery
and development, announces that at its Annual General Meeting held today,
Wednesday 23 May 2007, all resolutions put to the meeting were duly passed.


                                      -ends-



Notes to Editors


About Entelos


Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies and using 'virtual patients' to
revolutionize the way medicines are discovered, developed, and utilized. The
Company's core biosimulation computer models, known as PhysioLab(R) platforms,
are used to validate novel drug targets, select and develop compounds, assess
safety, optimize clinical trials and combination therapies, reprofile drugs,
evaluate in-licensing candidates, and better position existing products in
competitive markets. In addition to internal programs, Entelos partners with
global pharmaceutical and biotechnology companies and currently provides
scientific expertise and models in such areas as cardiovascular disease, asthma,
obesity, diabetes and rheumatoid arthritis, and complex physiological processes
such as hematopoiesis (anemia), cholesterol metabolism, and skin sensitization.





Enquiries
Entelos, Inc.

Jill Fujisaki,                 Tel: [phone]     [e-mail]
VP, Investor Relations                                                   
Brunswick Group
Justine McIlroy / Alex Tweed   Tel: [phone]
/Jon Coles                                 




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RAGFXLFLDEBLBBX